Schwartz Jonathan David 4/A

4/A · ROCKET PHARMACEUTICALS, INC. · Filed Feb 22, 2023

Form 4/AAmended

Period: 2023-02-14

See Remarks

Transactions

Exercise/Conversion
Restricted Stock Units
2023-02-14+8,574→ 17,410 total
→ Common Stock (8,574 underlying)
Exercise/Conversion
Common Stock
2023-02-14+8,574→ 98,103 total
Award
Stock Option (Right to Buy)
2023-02-14+124,496→ 124,496 total
Exercise: $20.04Exp: 2033-02-13→ Common Stock (124,496 underlying)
Award
Restricted Stock Units
2023-02-14+41,541→ 41,541 total
→ Common Stock (41,541 underlying)

Footnotes (6)

[F1]The original Form 4, filed on February 16, 2023, is being amended by this amendment to include the vesting of restricted stock units that took place on February 14, 2023.
[F2]Represents shares of Common Stock received upon vesting of a restricted stock unit award.
[F3]This option represents a right to purchase a total of 124,496 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
[F4]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F5]One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
[F6]One-third (1/3) of such restricted stock units became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Documents

1 file